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ABSTRACT
Background : The prognosis of  Hairy cell
leukemia (HCL) has improved markedly
following treatment with  cladribine (2-
CdA), a nucleoside analogue. We reviewed
data on patients with HCL treated in our
department.
Methods  Between 1995 and 2004,
23 patients with hairy cell leukemia (HCL)
were diagnosed   Patients median age was
48.5 years (range, 32 to 66 years), there
were 18 males and 5 females. The common
presenting symptoms were: fatigue (82.6%),
fever (34.7%), abdominal discomfort (21.7%),
arthralgia/bone pains (13%) and bleeding
(17.3%).  22 of 23 (95.6%) patients had
enlarged spleen, and hepatomegaly (65%).
Lymph node enlargement was present in
17% of  patients. Investigations revealed-
median Hb of 7.8g% (5.7 to 12.9 g%),
thrombocytopenia (median 55000/cmm)  and
median WBC count of 3500/cmm (range, 600
to 20,200/cmm). Bicytopenia or
pancytopenia was present in 87% and bone
marrow fibrosis in 75% of cases.  Immuno-
phenotyping studies revealed expression of
CD11C (60%), CD25 (60%), FMC7(47.8%),
CD23(34.8%), CD103 in 39% of cases.
20 of 23 patients received treatment; two
received treatment else where and one
patient died of liver failure prior to
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treatment.  17 of 20 patients were treated
with 2-CdA, 2 with interferon alfa (IFN-a)
and one patient underwent splenectomy
alone.  Three patients received 2-CdA as
second line therapy for treatment of relapse:
this includes  one patient each, treated
with IFN- a and splenectomy both and one
patient received 2-cdA twice in view of
relapse.
Results  Following treatment with 2CdA 
95% of patients responded; complete-84.2%
and partial response in 10.5%. one (5.2%)
patient died of  toxicity. Two patients
relapsed at a mean follow up of 25 months.
The common side effects were febrile
episodes (n=10) and grade I-II
myelosuppression. One patient died of
toxicity to 2-CdA. This patient was a known
case of multidrug resistant disseminated
tuberculosis. He had severe
myelosuppression with fungal sepsis with
multiorgan failure and BM Aspirate was
positive for AFB. Other infections
documented were Pulmonary tuberculosis in
2 and herpes zoster in one patient. The
patient who underwent Splenectomy
achieved remission but relapsed after  3
years and was salvaged with 2-CdA again.
Median time for normalization of blood
counts after 2-CdA was 28 days and median
time to regress spleen was 41.5 days .
Conclusion  Present study confirms good
outcome   with 2-CdA  (cladribine) therapy
for patients of hairy cell leukemia.
Original Article-1
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INTRODUCTION
Hairy cell leukemia (HCL), first described
by Bouroncle et al 1 in 1958 is an indolent
chronic B-cell lymphoproliferative disorder
(CLPD) involving the bone marrow and spleen.
It is an uncommon disease of middle  aged adults
and patients commonly present with
pancytopenia, splenomegaly and history of
repeated infections.  Its defining features are
mononeuclear cells with prominent cytoplasmic
projections, which contain tartarate resistant
acid phosphatase (TRAP) and show typical
pattern of  cellular infiltration in bone marrow
and spleen.  The morphologic findings on  the
bone marrow biopsy consists of a diffuse
infiltration by lymphocytes that are spaced
wider than expected  the fried-egg
appearance.  Reticulin staining is increased
reflecting the fibrosis, which accounts for the
difficulty usually encountered when attempting
to aspirate the bone marrow.
Immunophenotypic analysis of  the abnormal
cells in HCL reveals CD11C, CD19, CD20, CD22
CD25, CD103 and kappa or lambda light chain
positivity and the absence of CD5 and CD21
antigen expression 2-3.
Until 1984, splenectomy was the only
treatment for HCL ; this was associated with
normalization of  blood counts in 50-70% of
patients, with a median response duration of 5-
20 months and five year overall survival of
70%.3-4 Interferon alfa (IFN-a) was the first
systemic agent to induce complete remission in
this disease.  IFN-a-2b demonstrated an overall
response rate of 75% in untreated HCL patients
with complete responses (CR) in 5% of patients.5
In the past fifteen years, newer purine analogues
i.e.  2-deoxycofor mycin (DCF) and 2-CdA
(Cladribine) have revolutionized the treatment
of  HCL, both agents have potent
lymphocytotoxic activity and are capable of
producing faster and superior CR rates (80-90%)
than those observed with IFN-a.6-7  These results
have been confirmed in smaller studies reported
from India.  Abhayankar et al  reported  CR rate
of 100% in 18 HCL patients treated with 2-CdA.8
Jaynanth et al  reported CR rate of 93.7% in 15
patients of  HCL treated with cladribine.9  We
have recently analysed our experience with
hairy cell leukemia . This report describes the
results.
PATIENTS AND METHODS
Between Jan 1995 and Oct 2004, 23 consecutive
patients with symptomatic  HCL were seen at
our institute. Patients characteristics are
shown in table-I. All patients underwent detailed
clinical examination. The diagnosis was based
on clinical and hematological parameters mainly
bone marrow aspiration, trephine biopsy and
TRAP positivity.  The immunophenotype of
peripheral blood and bone marrow aspirate
using monoclonal antibodies (mAbs) and
flowcytometry was perfor med.  The
immunological diagnosis of hairy cells required
high reactivity with monoclonal antibodies CD
103 and the co-expression of Pan B cell antigens
CD19, CD20, CD22, CD11C, CD25 and FMC7 was
examined in 20 cases.
TREATMENT
The cladribine (2-CdA)  was given in 0.09mg/
kg/day dose for seven days as continuous 24-
hour intravenous infusion in normal saline
through central line on an in-patient basis.   All
patients had normal hepatic and renal functions.
Blood counts, differential counts and
biochemistry profile was done daily or alternate
day for first three weeks and later on once
weekly till normalization of  counts.  Two
patients received Interferon in the dose of 3-mU
subcutaneous thrice a week for 18-24 months.
One patient had underwent splenectomy  Packed
RBC and platelets concentrates were given for
hemoglobin less than 8.5gm% or symptomatic
anemia and platelets less than 20,000/cumm
respectively. All patients receiving 2-CdA, were
given prophylactic fluconazole and acyclovir for
atleast  12 weeks.  Patients also received PCP
(penumocystitis carinii) prophylaxis using
trimethoprim 15mg/kg twice a week for one
year.
RESPONSE ASSESSMENT
Patients were evaluated for response after
hematological recovery usually within 3-4 weeks
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after therapy.  Evaluation included - assessment
of clinical symptoms and signs, complete blood
counts and differential counts, bone marrow
examination for morphology and TRAP staining.
Patients were followed up every 2 months during
first year, 3 monthly in second year then at 4 - 6
months interval in 3rd year and thereafter.
Response criteria were defined according to NCI
guidelines. Briefly, complete remission (CR) was
defined as the regression of physical symptoms/
signs, ANC (absolute neutrophil count)
³1.5×109/L, Hb =12.0 gm/L, Platelets =100× 10
9
/L and the absence of hairy cells on peripheral
blood smear. Morphologic absence of  disease on
bone marrow aspiration and biopsy specimen
was required. Partial remission was defined as
decrease by more than 50% of hairy cells on
bone marrow biopsy and reduction by more than
50% of  hepato-splenomegaly.  No response  if  no
change or increase in the number of hairy cells
in the blood and bone marrow was observed.
Toxicity was graded according to NCIs common
toxicity criteria (NCI CTC Toxicity scale
version 2.0).
RESULTS
Patients median age was 48.5 years (range 32-66
years). Eighteen patients were male and five
were females (M: F ratio=78.2:21.8).  The most
common presenting symptoms were - fatigue and
fever followed by abdominal discomfort, joint
pain and bleeding.  The detailed clinical and
laboratory characteristics are summarized in
Table I & II
The median hemoglobin was 7.8gm/dl
(range 5.7-12.9/G %), median platelet count was
55,500/mm3 (range 32,000-1,  15,000/mm 3).
While the median TLC was 3500/mm3 (range
600-20,200). All the patients had hairy cells in
bone marrow and 75% had hairy cells in
peripheral smear.  Bone marrow was
hypercellular in 66%, normocellular in 25% and
hypocellular in 9% of  patients.  Bone marrow
fibrosis was documented in 75% cases.  The
TRAP positivity was found in 82.6% (Total 19)
and CD11C (60%) CD25 (60.0%), CDFMC-7
(47.8%), CD23 (34.7%) CD103 (39.1%) positivity
were detected.
20 patients received treatment; one
patient died prior to treatment due to  hepatic
encephalopathy possibly of viral origin,
however autopsy was not done, and two patients
received treatment elsewhere.  Among 20
patients, 17 received 2-CDA as primary therapy,
2 received IFN- a  and one underwent
splenectomy.  Of  the 2 patients treated with
IFN- a , one attained CR but relapsed after 3.5
years and received 2-CdA at the time of relapse
while the other patient attained partial
remission  and continues to have stable disease.
One  patient who underwent splenectomy
relapsed later and received 2-CdA for salvage.
Thus, a total of  19 patients received 2-CdA (17
as primary therapy and 2 as salvage ).  Of these
16 (84.2%) achieved CR and two patients had PR
(10.5%), giving an overall response rate of
94.7%.  Two patients treated with 2-CdA
relapsed within 3 years who on re-treatment
with  2-CdA achieved CR. The treatment
response is summarized in table III.
Toxicity : The drug was well tolerated.  The
immediate side effects were mild, most
commonly seen were - acute febrile episodes
(culture negative) seen in 10 patients (52.6%).
In six patients (6/10) fever lasted 24-48 hours
and probably was not infection related.
Remaining  four patients (4/10) with fever and
neutropenia  received  empirical IV antibiotics
and improved. One patient died due to severe
prolonged neutropenia with fungal pneumonia
and multi-organ failure.  He was a case of  pre-
existing disseminated multi drug resistant
(MDR) tuberculosis with  bone marrow  positive
for AFB.  Other common side effects were
neutropenia alone 5(26.3%), neutropenia and
thrombocytopenia - 6(31.5%) and fatigue in 4
(23%). During the long term follow up, late
opportunistic infections were seen in 3 patients
two developed pulmonary TB and another
patient had herpes zoster. None of  the patient
died of  drug related toxicity.
DISCUSSION
Hairy cell leukemia is a rare chronic
lymphoproliferative disorder, which accounts
for 2% of all adult leukemias in the United
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Table I: Patients Characteristics
Characteristics Present study Abhayankar et al Jayanth et al Cheson et al
 (8) (9) (10)
Total no. of patients 23 18 15 928
Age (years)
Range 32-66 37-61 34-68 25-94
Median 48.5 44 56.5 56
Sex
Male 18 (78.2%) 12(66.6%) 13(86.6%) 80%
Female 5 (21.8%) 6(33.4%) 2(13.4%) 20%
Clinical Feature
Fatigue 19(82.6%) 11(61.1%) 11(73.3%) -----
Fever 8(34.7%) 5(27.7%) 7(46.%) -----
Abdominal discomfort 5(21.7%) 11(61.1%) 94% 47%
Arthralgia/bone pain 3(13%) ----- ----- -----
Bleeding 4(17.3%) ----- ----- -----
Splenomegaly 22(95.6%) 11(61.1%) 94% 47%
Hepatomegaly 15(65.2%) 7(38.8%) 6(37.5%) 10%
Lymphadenopathy 4(17.3%) 2(11.1%) 4(25%) 9%
Previous treatment
Splenectomy 1(4.3%) 1(5.5%) ----- 27%
Interferon  a 2(8.6%) 4(22.2%) ----- -----
DCF ----- ----- ----- 8%
Radiothrapy ----- ----- ----- 1%
States.10   The incidence of HCL in India is
unknown. At our institute we could find only 23
cases over 10 years,  constituting 0.27% of all
cases of haematological malignancies seen
during  this  period.  Similarly,  in another major
cancer centre,  only 35 cases of HCL were
diagnosed  over 10 years period suggesting a low
incidence.8 Jayanth et al from South India  have
recently  reported  another case series of 15
patients over a period of  6 years.9 Clinical and
laboratory characteristics of our patients were
similar to those reported from other centers  in
India8-9 and  in a large multicentric study  from
USA.10
DCF - doxycorformycin
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Table II :  Laboratory Characteristics
Characteristics Present study Abhayankar Jaynath Cheson
et al (8) et al (9) et al (10)
Hemoglobin (gm%) <10gm%=87.5%
Median 7.8 8 .2 11.5
Range 5.7-12.9 5-11.2 3.9-17.4
Platelet (cmm) <100,000/cmm=93.75%
Median 55,500 1,54,000 87,000
Range 32,000-1,15,000 44,000-3,50,000 6000-7,07,000
TLC (cmm) ANC<500/cmm=62.5%
Median 3500 9300 3300
Range 600-20,200 2000-20,000 300-31,200
Cytopenias
Pancytopenia 12(52.17%) NA NA NA
Bicytopenia 8 (35%)
Monocytopenia 4 (17%)
Hairy cells in bone 23(100%) 32% NA NA
marrow
TRAP (positive) 19(82.6%) 100% NA NA
Flow cytometry
CD11c 14(60%) 100%
CD25 14(60%) 100% NA NA
FMC7 11(47.8%) 100%
CD23 8(34.8%) 44.4%
CD103 9(39.1%)
Bone Marrow
cellularity
Normal 25% NA NA NA
Increased 66%
Fibrosis 75%
NA-not available
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During the past few years the treatment of
HCL has changed  remarkably .  Earlier in 1970s
splenectomy  and  in 1980s interferon-a  were
the main treatments available. Deoxy
corformycin (pentostatin)  in early 1990s and
more recently cladribine (2-CdA) has
dramatically improved the clinical course and
outcome for patients with hairy cell Leukemia.
Both  these drugs result in high complete
remission (CR) rates. Remission  rates (complete
& partial) of 94% including CR rate of 84% in
our study is similar to those reported  from two
other centres in India (100% and 93%)8-9 and
abroad.10-13 In a larger group of 144 patients
reported by Piro et al, CR was obtained in 123
(85%) and PR in 17(12%) giving an overall
response rate of 97%.7   Cheson et al from NCI
in a large series of 979 patients reported an
overall remission rate of  87% (CR 50%, PR 37%)
at a median follow up of 52 month.10 In this NCI
study  CR rate ( 50%) was lower;  possibly due
to inclusion of large no of patients receiving
2-CdA as salvage therapy.
Although responses with 2-CdA in HCL
are durable in most patients,11-13 relapses can
occur in up to 20% after achievement of CR. In
our study, 2 patients (10.5%) relapsed at a
median follow up of  25 months. Both these
patients were asymptomatic and relapse was
diagnosed on routine  peripheral smear and bone
marrow examination. In a similar study from
Mumbai, India, 3 of 18 patients (16%) relapsed
at a median follow up of 16 months.8 While in
another  study from South India, one patient
(1/14) relapsed at a median follow up of 9.5
months.9 Relapse in most asymptomatic cases is
diagnosed  mainly  by morphological
reappearance of the hairy cells.  Relapse rates
are higher if more sensitive molecular means of
minimal residual disease assessment are used .
Asymptomatic relapse  is not an indication for
treatment. However, salvage treatment must be
considered for patients who are symptomatic or
having progressive cytopenia. In the present
study, both patients at  relapse were  treated with
2-CdA and achieved CR. Fludarabine or
rituximab has been used successfully for the
treatment of patients  refractory or resistant to
2CdA.14-15
The toxicity to 2-CdA in present study was
acceptable.  Culture negative febrile episodes
were the most common side effect  noted  in 10
(52.6%) patients . Fever following 2-CdA therapy
has been observed by others and  is presumably
due to release of cytokines and opportunistic
infections.7,10 In our study, among 6 patients
Table III :  Treatment Results
Response Present study Abhayankar Jaynath Cheson
et al (8) et al (9) et al (10)
No 19* 18 15 861
CR 16(84.2%) 18(100%) 14(93.7%) 50%
PR 2(10.5%) ---- 1(16.66%) 37%
CR+PR 18(94.7%) 18(100%) 15(100%) 87%
Relapse 2(10.5%) at 25 3(16.6%)  at 1(6.66%) at 9.5 134(18%) at
months 16 months months 52 months
Mortality 1(5.2%) 1(6.66%) 62(7%)
*17 patients received 2-CdA as primary treatment (CR-14, PR-2 and Died-1) and 2 patients were treated
with 2-CdA following relapse (CR-2)}
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(6/10) patients fever subsided in 24-48 hours
while remaining  four patients received
empirical antibiotics in view of  persistent fever.
The other toxicity was grade III-IV
myelosuppression with neutropenia in 5 (26.3%)
and both neutropenia and thrombocytopenia in
another 6 (31.5%) cases.  Myelosuppression
mainly, neutropenia and/or thrombocytopenia
has been reported in up to  70% of patients with
febrile episodes in 30-40% patients.8-9,16 G-CSF
can reduce the period of neutropenia in such
patients who are severely neutropenic and have
evidence of sepsis.16 It is important to note here
that the  patients of hairy cell leukemia are
prone for opportunistic infections and the risk
is further increased with administration of
cladribine as this drug is associated with severe
and prolonged lymphocytopenia with marked
reduction of CD4+cells. Reduction in cell
mediated immunity makes these patients prone
for opportunistic infections (tubercular,viral and
fungal).17 In our study two patients developed
pulmonary tuberculosis and one had herpes
infection. One patient in our study died due to
severe prolonged neutropenia with fungal
pneumonia and multiorgan failure that had
preexisting disseminated MDR tuberculosis and
bone marrow was also positive for AFB.
Therefore,  it is important that all patients on
cladribine therapy are monitored closely for
these complications and broad spectrum
antibiotics must be started on the earliest
suspicion of infection. Other side effects noted
in our study were fatigue, bodyache and nausea.
One patient during the follow up
developed idiopathic thrombocytopenic purpura
(ITP) which is a known complication of 2-CdA
therapy. Another potential complication of
prolonged immunosuppression is risk of
secondary malignancy after many years in
patients who are already prone because of the
disease- induced immunosuppression 10-13.  In our
study none showed malignancy although longer
follow up may be needed to assess the oncogenic
role of 2-CdA.
In conclusion, our study confirms the
efficacy and relative safety of 2-CdA in inducing
complete and long lasting remission in HCL
patients.
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